Essential Partners’s Akebia Therapeutics AKBA Stock Holding History

Essential Partners’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.37K	Sell	1,485 -1,865	-56%	-$2K	﹤0.01%	2066
2026 Q2	$3.82K	Buy	3,350 +2,736	+446%	+$3.26K	﹤0.01%	1665
2026 Q1	$853	Buy	+614	New	+$844	﹤0.01%	2288
2025 Q4	–	Sell	-550	Closed	-$1.5K	–	2776
2025 Q3	$1.5K	Buy	550 +13	+2%	+$43	﹤0.01%	1889
2025 Q2	$1.96K	Buy	+537	New	+$1.48K	﹤0.01%	1323

Other funds holding AKBA

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

CWA Asset Management Group Naples, Florida $3.39B AUM 25.16% 1-Year Est. Return

PFG Private Wealth Management Lutz, Florida $236M AUM 9.86% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Unified Investment Management Atlanta, Georgia $114M AUM 22.27% 1-Year Est. Return

IWN

Independent Wealth Network Urbandale, Iowa $397M AUM 20.36% 1-Year Est. Return

Legacy Private Trust Neenah, Wisconsin $1.83B AUM 13% 1-Year Est. Return

Northern Lights Advisors Seattle, Washington $192M AUM 14.28% 1-Year Est. Return

James J. Burns & Company Melville, New York $937M AUM 13.35% 1-Year Est. Return

Essential Partners's AKBA Position: Q3 2026 in Review

Essential Partners reduced its Akebia Therapeutics (AKBA) stake by 56% in Q3 2026, selling an estimated $2K and leaving 1,485 shares worth $1.37K. The position accounts for ﹤0.01% of the portfolio, ranked #2066.

Essential Partners first reported a position in AKBA in Q2 2025 and has held it in 5 quarters since. The position peaked at $3.82K in Q2 2026. 23 funds tracked by Wall St. Rank hold AKBA as of Q3 2026.

Essential Partners held 1,485 shares of Akebia Therapeutics worth $1.37K as of Q3 2026.
Essential Partners sold 1,865 Akebia Therapeutics shares in Q3 2026, an estimated $2K.
Akebia Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #2066 holding.
Essential Partners first reported a position in Akebia Therapeutics in Q2 2025 and has held it in 5 quarters since.
Essential Partners's Akebia Therapeutics position peaked at $3.82K in Q2 2026.
23 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.